BioVie to present additional Parkinson’s drug data at international conference
BioVie Inc (BIVI, BIVIW) will present additional data on its experimental Parkinson's drug, bezisterim, at the AD/PD 2027 conference in Barcelona. The data, from the Phase 2 SUNRISE-PD trial, showed significant improvements in motor and non-motor symptoms for patients with higher inflammation. The company reported a 1.23-point improvement in treated patients versus a 1.21-point worsening in the placebo group, with a p-value of 0.0006.
How this was made

The 30-second read
Why it matters
The statistically significant improvement in motor scores could accelerate the path to Phase 3 and attract partnership interest.
Market read
First‑report trial data provides fresh catalyst for BIVI and may influence broader neuro‑degeneration biotech valuations.
What to watch
Potential safety concerns or trial enrollment challenges not addressed in the release.
Background
BioVie is a clinical‑stage biotech focused on neuro‑inflammatory diseases.
Ticker impact
BioVie announced new Phase 2 SUNRISE-PD trial data showing statistically significant improvement in Parkinson's patients.
likely upward pressure as market prices in the favorable data.
Phase 2 data with significant p‑value is material for a biotech and can trigger re‑rating.
Market effects
May lift other Parkinson's disease therapeutics and biotech peers.
US biotech sector could see modest gains.
Highlights growing interest in anti‑inflammatory approaches for neurodegeneration.
Counterpoint
Skeptics may question durability of Phase 2 results and demand Phase 3 data before committing.
Key entities
- CompanyBioVie Inc
Developer of the experimental Parkinson's drug bezisterim.
- CompanyPentara Corporation
Partner presenting alongside BioVie at the conference.


